What are the pharmacokinetic and pharmacodynamic properties of pitolisant (selective histamine H3‑receptor inverse agonist)?

Pharmacokinetics and Pharmacodynamics of Pitolisant

Pitolisant is a selective histamine H3-receptor inverse agonist/antagonist with well-characterized pharmacokinetic properties including 90% oral absorption, 20-hour half-life, extensive hepatic metabolism via CYP2D6, and dose-proportional exposure reaching steady state by day 7. 1

Mechanism of Action (Pharmacodynamics)

Pitolisant functions as an antagonist/inverse agonist at histamine H3 receptors, binding with high affinity (Ki = 1 nM) and demonstrating no appreciable binding to other histamine receptor subtypes (H1, H2, or H4; Ki ≥10 µM). 1 While the precise mechanism underlying its therapeutic effects in excessive daytime sleepiness and cataplexy remains incompletely understood, efficacy is believed to be mediated through H3 receptor blockade, which disinhibits histaminergic neurotransmission and promotes wakefulness. 1

Receptor occupancy studies demonstrate that a 40 mg dose achieves 84% ± 7% H3 receptor occupancy in the human brain, confirming robust target engagement at therapeutic doses. 2

Cardiac Effects

• At the maximum recommended dose (35.6 mg daily): QTc prolongation of 4.2 msec
• At supratherapeutic exposures (3.8-fold higher): QTc increase of 16 msec (mean) 1

Pharmacokinetic Profile

Absorption

• Oral bioavailability: ~90% 1
• Time to peak concentration (Tmax): 3.5 hours (range: 2-5 hours) 1
• Food effect: No clinically significant impact with high-fat meals 1

Distribution

• Volume of distribution: ~700 L (5-10 L/kg) 1
• Protein binding: 91-96% 1
• Blood-to-plasma ratio: 0.55-0.89 1

Steady-State Exposure (35.6 mg once daily)

• Cmax: 73 ng/mL (range: 49.2-126 ng/mL) 1
• AUC: 812 ng·hr/mL (range: 518-1468 ng·hr/mL) 1
• Time to steady state: Day 7 1
• Dose proportionality: Linear, proportional increases in Cmax and AUC 1

Metabolism

Primary pathway: CYP2D6 (major), with CYP3A4 contributing to a lesser extent 1

Metabolites undergo further metabolism or conjugation with glycine or glucuronic acid. Critically, none of these metabolites possess pharmacological activity. 1

Elimination

• Half-life: ~20 hours (range: 7.5-24.2 hours) 1
• Apparent oral clearance: 43.9 L/hr 1
• Renal clearance: <2% of total clearance 1
• Urinary excretion: ~90% of dose (<2% unchanged drug) 1
• Fecal excretion: 2.3% 1

Special Populations

Pediatric Patients (Ages 7-17 Years)

Pediatric patients demonstrate substantially higher pitolisant exposure compared to adults, necessitating dose adjustments: 1, 3

• Ages 12-17 years:

  • Cmax: 2.2-fold higher
  • AUC: 2.0-fold higher

• Ages 7-11 years:

  • Cmax: 3.4-fold higher
  • AUC: 3.6-fold higher

The single-dose study in 24 pediatric patients with narcolepsy confirmed these age-dependent differences, with younger children showing 52% higher Cmax and 73% higher AUC compared to older pediatric patients. 3

Hepatic Impairment

Pitolisant is contraindicated in severe hepatic impairment (Child-Pugh C) as it has not been studied in this population. 1

For mild and moderate hepatic impairment, exposure increases significantly: 1

• Mild impairment (Child-Pugh A): Monitor patients; no dose adjustment required
• Moderate impairment (Child-Pugh B): Significant exposure increase; monitor and adjust dosage

Renal Impairment

Exposure increases with declining renal function: 1

• Mild impairment (eGFR 60-89 mL/min/1.73 m²): Modest increase
• Moderate impairment (eGFR 30-59 mL/min/1.73 m²): Moderate increase
• Severe impairment (eGFR 15-29 mL/min/1.73 m²): Substantial increase
• End-stage renal disease (eGFR <15 mL/min/1.73 m²): Unknown; not recommended 1

Dosage adjustment is recommended for patients with eGFR <60 mL/min/1.73 m². 1

CYP2D6 Poor Metabolizers

CYP2D6 poor metabolizers (3-10% of Caucasians, 2-7% of African Americans) exhibit 2.4-fold higher AUC compared to extensive metabolizers. 1

At steady state with 35.6 mg once daily in poor metabolizers:

• Cmax: 153 ng/mL (151-157)
• AUC: 1920 ng·hr/mL (1854-2000) 1

Dosage reduction is mandatory in known CYP2D6 poor metabolizers. 1

Age, Sex, Race, and Body Weight

No clinically significant differences in pharmacokinetics were observed based on:

• Age (18-82 years)
• Sex
• Race/ethnicity (Caucasians or Blacks)
• Body weight (48-103 kg) 1

Clinical Implications

Drug Interactions

Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, bupropion) significantly increase pitolisant exposure, requiring dose reduction. 1

Pitolisant reduces the effectiveness of oral contraceptives, necessitating alternative or additional contraceptive methods. 4

Safety Profile

Common adverse events include headache, insomnia, weight gain, and nausea, though none resulted in treatment cessation in clinical trials. 4 The drug demonstrates no abuse potential in preclinical models, contrasting with modafinil. 5

Pregnancy Considerations

Based on animal data, pitolisant may cause fetal harm; human data are insufficient to determine risk. The balance of risks and harms differs for pregnant and breastfeeding women. 4